Article Text

Download PDFPDF

Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America
  1. Daniel J Wallace1,
  2. Karin Tse2,
  3. Leslie Hanrahan3,
  4. Rupert Davies4 and
  5. Michelle A Petri5
  1. 1 Rheumatology, Cedars-Sinai Medical Center, West Hollywood, California, USA
  2. 2 Lupus Foundation of America, Washington, District of Columbia, USA
  3. 3 Research and Education, Lupus Foundation of America, Washington, District of Columbia, USA
  4. 4 Blackrock Pharmaceuticals, Marlow, UK
  5. 5 Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
  1. Correspondence to Dr Daniel J Wallace; danielwallac{at}gmail.com

Abstract

The majority of patients with SLE in the USA have been prescribed hydroxychloroquine (HCQ). Given more recent guidelines, the availability of only one strength (200 mg tablets) may limit the flexibility and ability to accurately dose patients with lupus. The Lupus Foundation of America undertook a survey to assess the current landscape of HCQ tolerability and adherence.

  • hydroxychloroquine
  • systemic lupus erythematosus
  • adherence

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors All authors were involved in the survey design. KT was involved in the acquisition of data. RD was involved in the data analysis and manuscript writing. All authors contributed to revisions and approval of the final version.

  • Funding This research conducted by the Lupus Foundation of America was supported by Blackrock Pharmaceuticals.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement No additional data are available.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.